The Sabin Vaccine Institute initiated a Phase 2 clinical trial of its Marburg vaccine candidate in the United States, marking an important step towards developing a preventative measure for this deadly disease. The trial, involving 200 volunteers across four U.S. sites, complements ongoing Phase 2 trials in Kenya and Uganda and a recently concluded trial in Rwanda. This research is particularly crucial given the increasing frequency of Marburg outbreaks and the current lack of approved vaccines.
The development of a Marburg vaccine holds significant implications for global public health. A successful vaccine would offer critical protection for frontline healthcare workers and communities facing outbreaks, potentially reducing mortality rates and mitigating the devastating impact of this highly infectious disease. This is especially vital in regions where Marburg is endemic or where healthcare systems are less equipped to manage outbreaks effectively. The US trial expands the research to non-endemic populations, contributing to a more comprehensive understanding of the vaccine’s safety and efficacy across diverse demographics.
The U.S. trial is a randomized, placebo-controlled, double-blind study evaluating the vaccine’s safety and immunogenicity over a year. It leverages the cAd3 platform, which has shown promise in earlier phases of research by generating robust immune responses. The trial is funded by the Biomedical Advanced Research and Development Authority (BARDA), reflecting a substantial investment in combating Marburg and other filovirus threats. Sabin has received significant funding from BARDA for this research, indicating the urgency and priority given to vaccine development for these diseases. A parallel Phase 2 trial for Sabin’s Sudan virus vaccine, also utilizing the cAd3 platform, is currently underway in Uganda and Kenya, with US trials planned for later this year.
This multi-faceted approach to vaccine development, encompassing trials in both endemic and non-endemic regions, signifies a crucial advancement in the fight against Marburg virus disease. The data generated from these trials will be instrumental in seeking regulatory approval and ultimately making this potentially life-saving vaccine available globally. The progress of this research offers a promising outlook for enhancing global preparedness and response capabilities for future Marburg outbreaks, contributing significantly to international public health security.
Source link: https://www.globenewswire.com/news-release/2025/04/16/3062642/0/en/Sabin-Begins-Marburg-Vaccine-Trial-in-U-S.html
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
